Answers are grounded in this paper and cite their sources.
Molecular docking and molecular dynamics simulations were used to assess whether simvastatin can bind the agonist-binding site of the GluA2 AMPA receptor. Its deprotonated hydroxy acid form showed the most favorable MM/GBSA binding energy of the three forms studied and contacted residues that also anchor kainate, such as Arg485. These results suggest that simvastatin can occupy the agonist-binding site, which may contribute to its reported neuroprotective and antiepileptic effects.
No takes yet. Share an insight, caveat, or question.
Martí et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: